Have you seen our new ‘How I treat…’ features? Become a member (it’s free!) and discover the latest advice from fellow clinicians here >>>

AACR19: gilteritinib improves survival for certain acute myeloid leukemia patients

Written by Jade Parker, Senior Editor

Photo credit The ADMIRAL Phase III trial has demonstrated that treatment with the FLT3-targeted therapeutic gilteritinib (Xospata®) improved survival for patients with relapsed or refractory acute myeloid leukemia (AML) harboring a FLT3 mutation compared with standard chemotherapy treatment. The findings were recently presented at the American Association for Cancer Research (AACR) Annual Meeting (Atlanta, GA, USA, 29 March–3 April 2019). The ADMIRAL trial included 371 patients, 247 were randomly assigned to gilteritinib and 124 to standard chemotherapy. At the time of final analysis, the patients assigned to gilteritinib were found to have a 36% reduction in risk of death compared...

To view this content, please register now for access

It's completely free